# Addex Therapeutics Cash Runway at Risk

> Addex Therapeutics' cash runway shrinks as it regains GABAB rights and faces funding pressure.
- Title: Addex Therapeutics Cash Runway at Risk | Shortify
- Summary: Addex Therapeutics' cash runway shrinks as it regains GABAB rights and faces funding pressure. Addex Therapeutics has a cash balance of CHF 767,000 and needs…
- Keywords: addex therapeutics, gabab, indivior, neurosterix, atm offering, cash runway, clinical pipeline, biopharmaceutical, Addex, Therapeutics, Cash, Runway
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/addex-therapeutics-adxn-cash-runway-and-returned-gabab-rights-set-the-risk
- Author: Newsdesk
- Published: 2026-09-29T14:02:31+00:00
- Read time: 1 min
- Topics: addex therapeutics, gabab, indivior, neurosterix, atm offering, cash runway, clinical pipeline, biopharmaceutical
## Addex Reports Q2 2026 Results
Addex reported Q2 2026 net loss of CHF 1.745 million.
## USD 2.8 Million Equity Raise
Addex raised USD 2.8 million through an at-the-market offering.
## Returned GABAB Rights
Addex regained GABAB substance-use-disorder rights from Indivior.
## Cash Balance Drops
Addex had CHF 767,000 cash at June 30, 2026.
## R&D Expense Cuts
Addex reduced H1 2026 R&D expense to CHF 74,000 from CHF 391,000.
## Neurosterix Phase 1 Data
Neurosterix expects Phase 1 data for NTX-253 in Q4 2026.
## Key takeaway

Addex Therapeutics has a cash balance of CHF 767,000 and needs funding to advance its GABAB pipeline after regaining rights from Indivior.